Evermay Wealth Management’s GE HealthCare GEHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.4K Sell
710
-66
-9% -$4.46K ﹤0.01% 357
2026
Q2
$49.7K Sell
776
-113
-13% -$7.43K 0.01% 358
2026
Q1
$63.3K Sell
889
-458
-34% -$36.1K 0.01% 299
2025
Q4
$110K Buy
1,347
+283
+27% +$22K 0.01% 250
2025
Q3
$79.9K Sell
1,064
-33
-3% -$2.46K 0.01% 289
2025
Q2
$81.3K Buy
1,097
+66
+6% +$4.59K 0.01% 286
2025
Q1
$83.2K Buy
1,031
+133
+15% +$11.4K 0.01% 280
2024
Q4
$70.2K Sell
898
-105
-10% -$8.92K 0.01% 290
2024
Q3
$94.2K Sell
1,003
-18
-2% -$1.51K 0.02% 272
2024
Q2
$79.6K Hold
1,021
– – 0.01% 291
2024
Q1
$92.8K Buy
1,021
+211
+26% +$17.6K 0.01% 285
2023
Q4
$62.6K Sell
810
-89
-10% -$6.23K 0.01% 305
2023
Q3
$61.2K Hold
899
– – 0.01% 286
2023
Q2
$73K Buy
899
+200
+29% +$16K 0.01% 275
2023
Q1
$57.3K Buy
+699
New +$49.9K 0.01% 289

Other funds holding GEHC

Evermay Wealth Management's GEHC Position: Q3 2026 in Review

Evermay Wealth Management reduced its GE HealthCare (GEHC) stake by 8.5% in Q3 2026, selling an estimated $4.46K and leaving 710 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #357.

Evermay Wealth Management first reported a position in GEHC in Q1 2023 and has held it in 15 quarters since. The position peaked at $110K in Q4 2025. 1,218 funds tracked by Wall St. Rank hold GEHC as of Q3 2026.

  • Evermay Wealth Management held 710 shares of GE HealthCare worth $46.4K as of Q3 2026.
  • Evermay Wealth Management sold 66 GE HealthCare shares in Q3 2026, an estimated $4.46K.
  • GE HealthCare made up ﹤0.01% of Evermay Wealth Management's portfolio in Q3 2026, its #357 holding.
  • Evermay Wealth Management first reported a position in GE HealthCare in Q1 2023 and has held it in 15 quarters since.
  • Evermay Wealth Management's GE HealthCare position peaked at $110K in Q4 2025.
  • 1,218 funds tracked by Wall St. Rank held GE HealthCare as of Q3 2026.

Based on Evermay Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.